Uncover key drivers, emerging technologies, and competitive movements shaping the her2-positive breast cancer market from 2026–2035 with trusted insights from The Business Research Company

By how much is the HER2-Positive Breast Cancer Market expected to grow between 2026 and 2030?

The her2-positive breast cancer market size has experienced robust growth in recent years. It is projected to increase from $10.93 billion in 2025 to $11.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. The growth observed in the historic period is attributable to the increasing identification of her2-positive cases, the expansion of targeted oncology drug approvals, the growth in hospital oncology infrastructure, the availability of monoclonal antibody therapies, and rising clinical trial activity.

The market size for her2-positive breast cancer is anticipated to experience substantial expansion over the upcoming years. It is forecast to ascend to $15.23 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. This projected increase can be attributed to several factors, including the increasing uptake of next-generation her2 inhibitors, broader penetration of biosimilars, a rising demand for precision oncology treatments, growing investment in targeted cancer research, and an increased focus on enhancing survival outcomes. Significant trends expected during the forecast period involve the increasing adoption of her2-targeted antibody therapies, expanding use of antibody-drug conjugates, the widening availability of companion diagnostic testing, an amplified focus on early-stage targeted treatment, and improved integration of combination therapy approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

Which Drivers Are Influencing Market Acceleration In The HER2-Positive Breast Cancer Market?

The widespread integration of immunotherapy is projected to stimulate the expansion of the HER2-positive breast cancer market in the future. This medical approach involves boosting or altering the immune system’s inherent capacity to combat illnesses like cancer, infections, and autoimmune conditions. Its increasing use stems from its power to improve the immune system’s detection and eradication of cancer cells, offering superior effectiveness and reduced adverse reactions compared to traditional therapies. For HER2-positive breast cancer, immunotherapy is beneficial as it strengthens the body’s immune response to identify and target HER2-overexpressing cancer cells, leading to better treatment results and a lower chance of the disease returning. As an illustration, in July 2023, the American Association for Cancer Research, a US-based entity, reported that the FDA had given its approval to 11 immune checkpoint inhibitors (ICIs) in 2023, with at least one ICI sanctioned for addressing 20 distinct cancer categories and for any solid tumor displaying particular molecular traits. Consequently, the robust embrace of immunotherapy is fueling the expansion of the HER2-positive breast cancer market.

What Segments Are Identified Within The Structure Of The HER2-Positive Breast Cancer Market?

The her2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation

5) By Other Treatment Types: Radiation Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

Which Trends Are Expected To Influence The HER2-Positive Breast Cancer Market In The Upcoming Years?

Companies operating in the HER2-positive breast cancer market are concentrating on developing innovative therapies, such as HER2-directed antibody-drug conjugates (ADCs), to refine and enhance patient treatment. HER2-directed antibody-drug conjugates (ADCs) are precise cancer treatments that connect an antibody specific to HER2 with a cytotoxic drug, delivering the medication directly to HER2-positive cancer cells for increased treatment effectiveness. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, introduced Trastuzumab deruxtecan. This advanced therapy was developed through a partnership between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate (ADC), delivers a cytotoxic drug specifically to HER2-positive cancer cells, offering a more targeted and potent treatment for patients.

Which Key Market Players Are Investing In Expansion And Innovation Within The HER2-Positive Breast Cancer Market?

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

Which Regions Are Projected To Dominate The HER2-Positive Breast Cancer Market In The Coming Years?

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-positive breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized HER2-Positive Breast Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20832&type=smp

Browse Through More Reports Similar to the Global HER2-Positive Breast Cancer Market 2026, By The Business Research Company

Metastatic Hr Her2 Breast Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.